Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

NCT03713905 | Completed Phase 1

• 1 other identifier: YH-S001-01
• Study Type: interventional
• Target: 293
• Locations: 1 country
• Sites: 1

Brief Summary

To investigate the safety and tolerability of GLS-010 in subjects with advanced solid tumors (mainly gastric cancer, esophageal cancer). To investigate the preliminary relationship between the expression of the ligand of PD-1 (PD-L1) and efficacy.

Conditions

Advanced Solid Tumors

Outcome Measures

Primary Outcomes (1)

• Safety and tolerability of GLS-010 by assessing the percentage of participants who experience a dose-limiting toxicity (DLT)

  To investigate the safety and tolerance profile tolerance profile and the preliminary anti-tumor activity of GLS-010 in subjects with advanced solid tumors ( gastric cancer, esophageal cancer)

  28 days after patient enrolled

Secondary Outcomes (4)

• Dose Escalation: Area under the plasma concentration time curve (AUC) of GLS-010

  within 2 years after patient enrolled

• severity, seriousness, and relatedness of adverse events

  within 2 years of last patient enrolled

• Dose Escalation: Maximum concentration (Cmax) of GLS-010

  within 2 years after patient enrolled

• Dose Escalation: Half life Period (t1/2) of GLS-010

  within 2 years after patient enrolled

Other Outcomes (1)

• The percent of PD-1 receptor occupancy

  within 2 years of last patient enrolled

Study Arms (1)

GLS-010

EXPERIMENTAL

Use Full-human anti-pd-1 monoclonal antibodies for treatment

Drug: GLS-010

Interventions

GLS-010 DRUG

Recombinant Human Anti-PD-1 Monoclonal Antibody

Also known as: Recombinant Human Anti-PD-1 Monoclonal Antibody

GLS-010

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Willingness to participate in the clinical trial. Provide written informed consent prior to any study-specific screening procedures. Willingness and capability to comply with the requirements of the study;
• Male or female, Age between 18 and 75 years old (margin included) on the day of signing informed consent.
• Imaging and histologically/cytologically confirmed diagnosis of advanced solid tumor;Dose escalation study: Subjects with advanced solid tumor (mainly gastric cancer, esophageal cancer)Expansion study: It is estimated that subjects with gastric cancer and esophageal cancer are to be enrolled. The specific cancer type is to be identified later regarding the dose escalation study result.
• Paraffin embedding sample or biopsy sample available during screening, or be willing to provide tissue from a newly obtained core or excisional biopsy.
• Have no effective standard treatment or are not respond to standard treatment.
• Must have at least one measurable lesion as defined per RECIST Version 1.1.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Has a predicted survival period ≥ 12 weeks.
• Demonstrate adequate organ and hematopoietic function as defined below. a) Hemoglobin (HGB)≥90 g/L;b)White blood cell count (WBC) ≥3×109/L;c)Absolute neutrophil count (ANC) ≥1.5×109/L;d)Platelets ≥100×109/L;e) Serum total bilirubin (TBIL) ≤ 1.5 X upper limit of normal ULN;f) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 X ULN or ≤5 X ULN for subjects with liver metastases;g)Serum creatinine ≤1.5 X ULN;h)International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN.
• Since signing the ICF, female or male subjects of childbearing potential should be willing to use an adequate method of contraception with the spouse for the course of the study through 5 months after the last dose of study medication

You may not qualify if:

• Subjects with meningeal or symptomatic central nervous system metastases.
• Patients with any autoimmune disease, i.e., but not limited to, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (hypothyroidism without clinical symptoms or caused by radiotherapy and chemotherapy can be included); Patients with vitiligo or asthma CR in Childhood, not requiring any intervention in adulthood are permitted to enroll.; patients with asthma requiring a bronchiectasis intervention are not permitted to enroll.
• Subjects who require systemic corticosteroids (at doses equivalent to or greater than 10 mg/day of prednisone) or other immunosuppressive drugs within 14 days prior to or during the study.
• Subjects who have received anti-tumor vaccine or who have received anti-tumor drug treatment with immune-stimulating effect within 4 weeks prior to screening.
• Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti CTLA-4 antibody (including Ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
• Presence of other active cancers within 5 years prior to enrollment. Patients with cervical carcinoma in situ/ cured skin basal cell carcinoma who have received definitive adequate treatment are eligible.
• Participants with active viral hepatitis (positive HepB sAg and/or positive HepB core Ab with positive HepB DNA\>103 copies/mL, or positive HepC antibody), or syphilis positive.
• Subjects with a history of infection with human immunodeficiency virus, or other acquired, congenital immunodeficiency disease, or organ transplantation.
• Subjects with active tuberculosis infection or active tuberculosis infection within 1 year prior to administration, or subjects with active tuberculosis infection more than 1 year prior to administration without formal treatment.
• Subjects with active infection or unexplained fever \>38.5℃ during screening and prior to first administration (subject with fever caused by tumor may be included in the group as determined by the investigator).
• History of allergic reactions attributed to any macromolecular protein preparation/monoclonal antibody, or any other composition of the study drug.
• Investigational drug therapy outside of this trial during or within 4 weeks prior to administration.
• Has had prior chemotherapy, radiation therapy, targeted small molecule therapy or major surgery within 2 weeks prior to administration; who has not recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent (alopecia excluded)
• Poorly controlled heart disease, such as uncontrolled hyper hypertension, unstable angina pectoris, myocardial infarction within 6 months prior to screening, arrhythmias(including male QTc intervals≥ 450 ms, female QTc intervals≥ 470 ms, QTc intervals calculated by Formula Fridericia).
• Has history of Interstitial Lung Disease or non-infectious pneumonitis. (Patients caused by radiotherapy are eligible)

Sponsors & Collaborators

• Guangzhou Gloria Biosciences Co., Ltd.: lead

Study Sites (1)

Peking University Cancer Hospital & Institute

Beijing, Beijing Municipality, China

Location

Related Publications (1)

• Liu D, Ma C, Lu P, Gong J, Ye D, Wang S, Peng P, Bai Y, Song Y, Chen J, Jiang O, Zhang G, Ba Y, Chen L, Pan J, Li Q, Zhang L, Gu S, Yin X, Cao B, Han W, Dong H, Guo J, Zhang H, Su H, Jiang Y, Ouyang W, Ma L, Sun Y, Zhang F, Lv J, Guo Y, Xu C, Qi J, Wang L, Wang X, Liu Z, Shen L. Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma. Eur J Cancer. 2021 May;148:1-13. doi: 10.1016/j.ejca.2021.01.020. Epub 2021 Mar 7.

  PMID: 33691262 DERIVED

MeSH Terms

Interventions

zimberelimab

Study Officials

• Lin Shen, MM

  Peking University Cancer Hospital & Institute

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: 1 mg per kg, Q2W; 4 mg per kg, Q2W; 10 mg per kg, Q2W; 240 mg fixed dose, Q2W

Study Record Dates

• First Submitted: September 25, 2018
• First Posted: October 22, 2018
• Study Start: July 1, 2017
• Primary Completion: February 28, 2022
• Study Completion: February 28, 2022
• Last Updated: April 10, 2023

Record last verified: 2023-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)